US 12,252,701 B2
Chimeric antigen receptor T cell therapy
Adrian Bot, Beverly Hills, CA (US); and Michael David Mattie, Torrance, CA (US)
Assigned to KITE PHARMA, INC., Santa Monica, CA (US)
Filed by KITE PHARMA, INC., Santa Monica, CA (US)
Filed on Feb. 20, 2021, as Appl. No. 17/180,754.
Claims priority of provisional application 63/125,633, filed on Dec. 15, 2020.
Claims priority of provisional application 63/060,819, filed on Aug. 4, 2020.
Claims priority of provisional application 63/044,676, filed on Jun. 26, 2020.
Claims priority of provisional application 63/031,224, filed on May 28, 2020.
Claims priority of provisional application 63/010,240, filed on Apr. 15, 2020.
Claims priority of provisional application 62/979,001, filed on Feb. 20, 2020.
Prior Publication US 2022/0016165 A1, Jan. 20, 2022
Int. Cl. C12N 15/86 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01)
CPC C12N 15/86 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2319/30 (2013.01)] 16 Claims
 
1. A method of increasing the efficacy or reducing the toxicity of immunotherapy, bi-specific T-cell engagers (BiTEs), or immune checkpoint blockade treatment in a subject in need thereof, comprising:
(i) administering to the subject a JAK/STAT inhibitor and decreasing the subject's systemic inflammatory state; or
(ii) administering to the subject a JAK/STAT inhibitor and reducing the activity of myeloid cells, MCP-1, IL-6, or activated T cells in the subject,
prior to, during, or after immunotherapy, BiTEs, or immune checkpoint blockade treatment, or T cell immunotherapy, wherein the JAK/STAT inhibitor is filgotinib metabolite GS-829845 and is administered to the subject in need thereof at a dose of about 200 mg one or more times, optionally daily, and
(iii) further comprising administering to the subject a monoclonal antibody against monocyte chemoattractant protein-1 (MCP-1).